How Real World Data Improves Neurology Clinical Trials

Oncology trials can fill a roster in weeks. Neurology trials routinely take 12 to 18 months to recruit a single cohort, sometimes longer. That gap isn't really about how hard the disease is to treat. It comes down to two things: neurological diagnoses take longer to confirm than most conditions, and the details that actually decide who's eligible rarely live anywhere a database can search.

Real world data clinical trials work is how sponsors are starting to close that gap, not as a rescue tool pulled out after a trial has already stalled, but as something protocol teams use before a trial ever opens. Roughly 80% of clinical trials miss their original enrollment timeline (Online Patient Recruitment in Clinical Trials: Systematic Review and Meta-Analysis, PMC), and neurology carries more of that burden than most fields. The reason traces back to how these diseases actually get diagnosed and documented in the first place.

What Is Real World Data, and Why Neurology Depends on It More Than Most Fields

Real world data healthcare sources, EHRs, claims, registries, biomarker repositories, capture how patients get diagnosed and treated outside a trial protocol. Two things about neurology specifically make this data more important here than in most other therapeutic areas.

Diagnosis itself takes longer. Neurological disease rarely shows up with one confirmatory test the way some conditions do. Symptoms overlap across diagnoses. Patients bounce between specialists before anyone lands on a confirmed answer, and by the time that happens, the disease may have already moved past a trial's inclusion window.

Then there's the documentation problem. The details that actually define eligibility, relapse history, functional and cognitive scores, imaging findings, usually end up in a clinician's note rather than a coded field. Generic data extraction tools tend to hit a wall well before they can reliably pull that kind of detail out, because neurology documentation uses terminology and reasoning patterns that fall outside what those tools were trained on.

Testing Eligibility Criteria Before Protocol Lock

Most teams still treat real world data as something to call in after enrollment has already gone sideways. A better approach uses it earlier, to test draft eligibility criteria against the real patient population before a protocol gets finalized. That kind of protocol optimization tends to run through three phases.

• Feasibility diagnosis: Every inclusion and exclusion criterion gets scored three ways: how often the underlying variable actually shows up in structured fields, what share of the population clears the criterion on its own, and how much extra attrition it adds once it's stacked on top of everything else. That last number, marginal attrition, is what tells you which single rule is doing the most damage.
• Population modeling: The full draft protocol runs as a sequential cohort funnel against real patient data, to find the point where the eligible population actually collapses. Layering in public competitive-trial data adds another dimension: how many other studies in the same indication are already pulling from the same pool of patients.
• Scenario modeling: For each bottleneck, alternative versions of the criterion get tested against the same data. A wider age range, a different biomarker lookback window, a validated proxy instead of a stricter direct measure. What comes out the other end is a trade-off matrix showing exactly what each change would cost or gain in eligible patients.

The Cost of Getting This Wrong

Protocol amendments made mid-trial are expensive by design. The median direct cost of a substantial Phase III amendment runs about $535,000, and more than half of all protocols end up needing at least one (Getz et al., Therapeutic Innovation & Regulatory Science, 2016). Neurology and CNS trials see screen failure rates around 57%, against 36.3% across other therapeutic areas, and that number climbs well past that in some Alzheimer's protocols specifically. Testing criteria against real data before lock is a lot cheaper than finding out the same thing after sites have already started screening patients.

What Changes When Criteria Get Tested Early

The practical shift isn't really about new technology so much as when the technology gets used. A feasibility question that used to mean a formal data request, an analyst queue, and a wait of a week or more can instead get answered against real patient records while a protocol is still a draft. That changes what's possible at the design stage in a few concrete ways.

• Criteria stop being guesses. An eligibility rule can be checked against an actual population before it ever reaches a site coordinator, instead of being validated by whether patients show up or don't.

• Site selection gets sharper. Knowing where the eligible population actually concentrates, and which other trials are already drawing from it, changes which sites get activated first.

• Amendments become rarer, not just faster. Catching a restrictive criterion in review means it never needs a formal amendment later, which is a different, better outcome than simply amending faster once a problem shows up.

How NeuroDiscovery AI Supports Real World Data Clinical Trials Work

NeuroDiscovery AI runs a neurology-focused real world data platform covering 6M+ patient records and 3M+ active patients, across 1,000+ providers and 100+ clinical sites in 16+ U.S. states. The platform pulls clinical detail straight out of unstructured documentation, relapse history, functional scores, imaging findings, rather than relying only on coded fields. That's the piece that makes criterion-by-criterion feasibility testing possible before a protocol ever reaches a site.

Benefits of Building Protocols on Real World Data

• Fewer post-lock amendments. Criteria get stress-tested against the real patient population before a protocol is finalized, not after sites start screening.

• Realistic feasibility estimates. Population modeling shows the actual addressable cohort instead of an estimate built on published literature alone.

• Faster site activation. Competitive trial context helps sponsors avoid activating sites that are already competing for the same patients.

• Trade-offs you can actually defend. Scenario modeling puts a number on what a criterion change costs or gains, instead of leaving it to judgment alone.

Conclusion

Neurology's enrollment problem was never really about a shortage of eligible patients. It's a shortage of visibility into who those patients are before a protocol gets locked. Real world data infrastructure built to pull clinical detail out of unstructured documentation gives protocol teams visibility early enough to actually use it, instead of finding out the hard way through a missed enrollment target or a six-figure amendment.